Efinopegdutide helped resolve inflammatory liver disease
At 52 weeks, resolution without worsening liver scarring occurred in 56%, 63% and 61% at three efinopegdutide doses, versus 13% with placebo.At 52 weeks, resolution without worsening liver scarring occurred in 56%, 63% and 61% at three efinopegdutide doses, versus 13% with placebo.